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Depression Is Associated With Decreased Blood Pressure,
but Antidepressant Use Increases the Risk for Hypertension
Carmilla M.M. Licht, Eco J.C. de Geus, Adrie Seldenrijk, Hein P.J. van Hout, Frans G. Zitman,
Richard van Dyck, Brenda W.J.H. Penninx
Abstract—The present study compared blood pressure levels between subjects with clinical anxiety and depressive
disorders with healthy controls. Cross-sectional data were obtained in a large cohort study, the Netherlands Study of
Depression and Anxiety (N2981). Participants were classified as controls (N590) or currently or remittedly
depressed or anxious subjects (N2028), of which 1384 were not and 644 were using antidepressants. Regression
analyses calculated the contributions of anxiety and depressive disorders and antidepressant use to diastolic and systolic
blood pressures, after controlling for multiple covariates. Heart rate and heart rate variability measures were
subsequently added to test whether effects of anxiety/depression or medication were mediated by vagal control over the
heart. Higher mean diastolic blood pressure was found among the current anxious subjects (0.932; P0.03),
although anxiety was not significantly related to hypertension risk. Remitted and current depressed subjects had a lower
mean systolic blood pressure (1.74, P0.04 and 2.35, P0.004, respectively) and were significantly less
likely to have isolated systolic hypertension than controls. Users of tricyclic antidepressants had higher mean systolic
and diastolic blood pressures and were more likely to have hypertension stage 1 (odds ratio: 1.90; 95% CI: 0.94 to 3.84;
P0.07) and stage 2 (odds ratio: 3.19; 95% CI: 1.35 to 7.59; P0.008). Users of noradrenergic and serotonergic
working antidepressants were more likely to have hypertension stage 1. This study shows that depressive disorder is
associated with low systolic blood pressure and less hypertension, whereas the use of certain antidepressants is
associated with both high diastolic and systolic blood pressures and hypertension. (Hypertension. 2009;53:631-638.)
Key Words: depression  anxiety disorder  blood pressure  hypertension  autonomic nervous system
 antidepressants
.
High blood pressure (BP) is an important risk factor forcardiovascular disease (CVD)1,2 and may be more prev-
alent in persons with psychopathology.3–6 This has led to the
hypothesis that BP can explain part of the well-known
association between psychopathology and CVD.7 However,
studies investigating the association between BP and psycho-
pathology have not produced consistent results, particularly
for the 2 major classes of psychiatric ailments, anxiety
disorders and major depressive disorder. Some studies ob-
served increased BP or hypertension among persons with
depressive8,9 and anxiety disorders,4,10 whereas others found
no association4,11,12 or even a decreased BP in depressed or
anxious patients.10,13,14 For example, a study of Hildrum et
al13 observed a significant lower BP in persons with
depressive or anxiety disorders and additionally reported
that symptoms of anxiety and depression predict low BP
over time.14
This lower BP in anxious and depressed subjects is
enigmatic and contrasts with the hypothesis that BP can
explain part of the well-known association between psycho-
pathology and CVD.7 It is also hard to reconcile with the low
cardiac vagal control (CVC) observed in anxious and de-
pressed patients,15–17 because low BP is typically accompa-
nied by high CVC.18,19 A possible explanation for the current
state of affairs is that antidepressant use acts to confound the
relationship between psychopathology and BP. In 2 recent
studies in a large cohort of 2179 depressed and anxious
patients compared with 616 controls,16,17 it was found that the
association between CVC and depression and anxiety was
largely driven by the use of antidepressants. Significant
decreases in CVC were observed in users of tricyclic antide-
pressants (TCAs), selective serotonin reuptake inhibitors
(SSRIs), and noradrenergic and serotonergic (NS) working
antidepressants. The largest effects were seen in TCA users,
who also had a significant increase in heart rate (HR), which
is in line with the conclusions from a recent review on the
autonomic effects of antidepressants.20
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The present study addresses the important clinical question
of whether anxiety and depressive disorders are associated
with BP, either by themselves or when combined with the use
of antidepressant medication.
Methods
Subjects
Subjects participating in the present study came from the Nether-
lands Study of Depression and Anxiety, an ongoing cohort study
among 2981 adult subjects (18 to 65 years) to examine the course of
depressive and anxiety disorders. Methods and recruitment strategy
have been described elsewhere.21 The Netherlands Study of Depres-
sion and Anxiety sample consists of 652 persons without depressive
or anxiety disorders and 2329 with a (remitted or current) diagnosis
of depressive or anxiety disorder. To represent various settings and
stages of psychopathology, depressed or anxious subjects were
recruited in different settings: community, primary care, and mental
health care organizations. Community-based subjects had been
identified previously in a population-based study; primary care
subjects were identified through a 3-stage screening procedure
(involving the K1022 and the short-form Composite International
Diagnostic Interview by telephone) conducted among patients of 65
general practitioners, and mental health care patients were recruited
when newly enrolled at 1 of the 17 participating mental health
organization locations.
Subjects were assessed between September 2004 and February
2007 during a 4-hour clinic site visit in which the presence of
depressive and anxiety disorders was ascertained using the lifetime
version of the Composite International Diagnostic Interview psychi-
atric interview (World Health Organization version 2.1). The Com-
posite International Diagnostic Interview establishes diagnoses ac-
cording to the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, criteria23 and has shown high interrater
and test-retest reliability and high validity for depressive and anxiety
disorders.24
To test whether main sample and BP characteristics differed
between persons with and without psychopathology and using and
not using medication, 3 clearly distinct groups were created for the
present study. The first group consisted of 590 control subjects with
no lifetime history of anxiety or depressive disorders and not using
an antidepressant. The second group consisted of 1348 persons with
a major depressive disorder (MDD) or an anxiety disorder diagnosis
(panic, social phobia, or generalized anxiety disorder) who did not
take antidepressants. The third group consisted of 644 persons with
a Composite International Diagnostic Interview–confirmed MDD or
anxiety disorder who did use an antidepressant (see below). The
remaining 363 Netherlands Study of Depression and Anxiety sub-
jects were excluded from the analyses: 184 patients had a CVD
(self-reported diagnosis of coronary disease, cardiac arrhythmia,
angina, heart failure, or myocardial infarction, confirmed with the
use of cardiovascular medication) or underwent an operation for
heart or coronary problems and were excluded for analyses because
of the possible interfering, confounding effects of CVD; 61 subjects
did not meet the group criteria (eg, persons with minor depression or
controls using an antidepressant); 8 persons had missing BP data;
and 112 persons had missing physiological data because of equip-
ment failure during assessment or poor ECG quality.
For additional analyses on the importance of specific psychopa-
thology characteristics, an indicator was created to differentiate
persons with a remitted MDD or anxiety diagnosis (lifetime diagno-
sis not present in the last 6 months) and those with a current MDD
or anxiety diagnosis (present in the last 6 months). The use of
medication was determined by copying medicine names from the
containers brought in by all of the participants. Frequently used
medications (50% of all days in past month) were classified using
the World Health Organization Anatomic Therapeutic Chemical
(ATC) classification.25 We distinguished SSRIs (ATC code
N06AB), TCAs (ATC code N06AA), and other NS working antide-
pressants (antidepressants classified as N06AX: selective serotonin
and noradrenalin reuptake inhibitors and noradrenergic and specific
serotonergic antidepressants).
Measurements
The clinic visit consisted of a blood draw, a medical examination
including BP measurements, a psychiatric interview, and adminis-
tration of several written questionnaires concerning, eg, mood state,
lifestyle, and medical history. The study protocol was approved by
the ethical review board of participating centers, and all of the
participants signed informed consent.
BP and Hypertension
BP was registered by the OMRON IntelliSense Professional Digital
Blood Pressure Monitor, HEM-907XL (Omron Healthcare, Inc).
Systolic BP (SBP) and diastolic BP (DBP) were measured twice
during supine rest on the right arm and were averaged over the 2
measurements. A correction was made for all of the individuals on
hypertensive medication, which was considered as being used if
subjects frequently (50% of days in last month) used antihyper-
tensives (ATC code C02), diuretics (ATC code C03), -blocking
agents (ATC code C07), or calcium channel blockers (ATC code
C08). In accordance with earlier studies and based on the efficacy of
antihypertensive drugs in randomized trials,26,27 we added 10 mm Hg to
SBP and 5 mm Hg to DBP for subjects who used antihypertensives.
In addition to these continuous SBP and DBP variables, we also
created a 5-category hypertension indicator following American
Heart Association guidelines28,29 ranging from no hypertension
(medication-corrected SBP 140 mm Hg and medication-corrected
DBP 90 mm Hg), isolated systolic hypertension (SBP 140 mm Hg
and DBP 90 mm Hg), isolated diastolic hypertension (SBP
140 mm Hg and DBP 90 mm Hg), and hypertension stage 1
(SBP 140 mm Hg and DBP 90 mm Hg) to hypertension stage 2
(SBP 160 mm Hg and DBP 100 mm Hg).
Autonomic Nervous System Function
HR was extracted from a 3-lead ECG signal that was measured using
the Vrije Universiteit Ambulatory Monitoring System. The Vrije
Universiteit Ambulatory Monitoring System is a lightweight ambu-
latory device recording the ECG and changes in thorax impedance
from 6 electrodes placed at chest and back of the subjects.30,31 CVC
was assessed by HR variability in the respiratory frequency range,
known as respiratory sinus arrhythmia (RSA) by peak-valley esti-
mation, using the combined ECG and thorax impedance signals to
obtain the differences between the shortest beat during inspiration
and the longest beat during expiration.32 RSA by peak-valley
estimation is highly correlated with high-frequency power of the
internal beat interval (IBI) time series as obtained by Fourier or
Wavelet analysis, but the advantage of RSA by peak-valley estima-
tion assessments is that these additionally consider respiration rate
and, consequently, do not suffer from potential confounding by
individual differences in respiratory behavior.32,33
Subjects were wearing the monitoring device during the clinic
visit. Movement registration through vertical accelerometry was
used to excise periods where subjects were nonstationary and when
subjects changed interview condition. For congruency, only the RSA
by peak-valley estimation and HR data recorded during the period of
BP recording were used in the analyses (average registration: 9.7
minutes).
Covariates
Sociodemographics included age, sex, and education in years. In
addition, various health indicators were considered as covariates,
because these have been linked to both hypertension and psychopa-
thology. Body mass index was determined as measured weight in
kilograms divided by the square of the measured height in meters.
Physical activity was measured using the International Physical
Activity Questionnaire34 and expressed in the multiple of one’s
resting metabolic rate times minutes of physical activity per week.
Smoking status was categorized as nonsmoker versus smoker, and
alcohol use was defined as the number of alcoholic consumptions a
632 Hypertension April 2009
 at Vrije Universiteit--Amsterdam on May 12, 2009 hyper.ahajournals.orgDownloaded from 
day. Self-reports were used for the ascertainment of the presence of
chronic conditions (epilepsy, diabetes mellitus, osteoarthritis, stroke,
cancer, lung disease, thyroid disease, liver disease, chronic fatigue
syndrome, intestinal disorders, or ulcer).
Statistical Analyses
Data were analyzed using SPSS 15.0. Characteristics across the 3
psychopathology-medication groups (controls, MDD or anxiety
disorder without medication, and MDD or anxiety disorder on
medication) were compared using ANOVA and 2 statistics.
ANOVA was conducted to compare SBP and DBP between the
further divided remitted and current specific psychopathology groups.
Effect sizes were calculated with Cohen’s d, defined as the difference
in the mean SBP or DBP between groups, divided by the pooled SD
of these groups.
To examine whether psychopathology and antidepressant use were
associated with BP, we conducted linear regression analyses with the
normally distributed continuous SBP and DBP variables as outcomes.
First, we entered current and remitted MDD and anxiety and antidepres-
sant use; in 3 additional steps, we further entered the covariates, and then
RSA and HR, to explore whether observed associations were because of
autonomic nervous system effects. Finally, we conducted multinomial
regression analyses with the clinical hypertension groups as outcome,
using the group without hypertension as a reference and dichotomous
variables for psychopathology and antidepressant use as interest vari-
ables, in which we also adjusted for covariates.
Results
The mean age of the study sample (N2618) was 40.9 years
(SD: 13.0), 67.9% were women, and 49.0% had12 years of
education. Table 1 shows the demographic characteristics,
lifestyle and health factors, antidepressant use, psychopathol-
ogy, autonomic nervous system activity measures, and mean
BP according to psychopathology/medication status. Com-
pared with controls, subjects with psychopathology were a
little older, more often female, lower educated, had a higher
body mass index, were less physically active, were more
often smokers but drank less, and had more diseases. Of the
subjects with psychopathology using medication, 67 used a
TCA, 442 used an SSRI (no TCA), and 135 used an NS
working antidepressant (no TCA or SSRI). There were no
differences in the prevalence of antihypertensive medication
Table 1. Main Sample Characteristics for Controls, Individuals With Psychopathology not Using
Antidepressants, and Individuals With Psychopathology Using Antidepressants
Characteristics
Control
(N590)
Psychopathology Without
Antidepressant (N1384)
Psychopathology Using
Antidepressant (N644) P *
Demographics
Age, meanSD, y 40.414.6 40.612.9 42.011.3 0.03
Sex, % female 62.5 69.8 68.6 0.006
Education, meanSD, y 12.93.2 12.23.2 11.73.4 0.001
Lifestyle and health factors
BMI, meanSD, kg/m2 24.94.5 25.24.7 26.15.7 0.001
Physical activity, meanSD, 1000
METmin/wk
3.93.1 3.83.0 3.43.2 0.009
Smoking, % yes 26.2 39.6 46.7 0.001
Alcohol, meanSD, No. of consumptions
per day
1.01.3 1.01.5 0.91.5 0.03
Antihypertensives, % yes 11.4 9.0 11.2 0.15
Chronic diseases, meanSD, n 0.981.0 1.261.2 1.291.3 0.001
Antidepressant use
TCA, % yes 0 0 10.4 0.001
SSRI, % yes 0 0 68.6 0.001
NS working antidepressants, % yes 0 0 21.0 0.001
Psychopathology†
Current MDD, % yes 0 40.7 66.9 0.001
Remitted MDD, % yes 0 39.7 24.7 0.001
Current anxiety disorder, % yes) 0 46.7 65.1 0.001
Remitted anxiety disorder, % yes 0 21.8 14.4 0.001
Autonomic nervous system activity
HR, meanSD, bpm 72.38.9 71.99.4 73.010.3 0.05
RSA, meanSD, ms 48.931.2 48.025.3 36.620.4 0.001
Blood pressure
SBP, meanSD, mm Hg 136.319.6 133.918.9 136.219.0 0.008
DBP, meanSD, mm Hg 80.411.2 80.510.8 82.711.2 0.001
MET indicates multiple of the resting metabolic rate.
*Comparison was performed using ANOVA analyses (continuous variables) and 2 statistics (categorical variable).
†Percentages of MDD and anxiety disorder do not add up because of comorbidity.
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across the 3 psychopathology/medication groups (overall
prevalence: 10.1%).
The Figure presents the results of the unadjusted ANOVA
analyses on SBP and DBP as a function of psychopathology
and antidepressants use. Results show that SBP and DBP did
not differ between subjects with anxiety disorders and con-
trols. Subjects with MDD, however, had significantly lower
SBP than controls (remitted diagnosis: P0.02 and Cohen’s
d0.155; current diagnosis: P0.002 and Cohen’s d0.184).
No depression-related differences in DBP were found. In
addition, the Figure clearly shows that subjects using a TCA
had a higher SBP (P0.003; d0.388) and DBP (P0.001;
d0.794), and those using an NS working antidepressant had
a higher DBP (P0.001; d0.348).
Table 2 presents the results of the linear regression analy-
ses. The unadjusted model generally shows the same results
as the ANOVA analyses reported in the Figure, with the
exception that NS working antidepressants are also associated
with increased SBP. Adjusting for covariates did not change
the overall pattern of results, but the effects of NS working
antidepressants on SBP disappeared, and a positive associa-
tion between current anxiety and DBP appeared. Additional
adjustment for RSA and HR removed the effect of NS
working antidepressants on DBP and the effect of TCAs on
SBP and greatly reduced their effects on DBP ( decreased
from 5.47 to 3.06). This suggests that the effects of TCA and
NS working antidepressants on BP are mediated in part by
lowered CVC over HR.
Importantly, the final models show that both remitted
(1.74; P0.04) and current (2.35; P0.004)
MDDs remain associated with a lower SBP value even after
correcting for antidepressant use, RSA, and HR. In addition,
current anxiety disorder remained significantly associated
with higher DBP (0.93; P0.03). Both results remained
intact in secondary analyses that excluded the subjects using
antihypertensive medication.
Table 3 shows the results of the multinominal logistic
regression analysis using hypertensive status as the outcome
measure. Of the total sample, 36.3% (N950) met the
definition of hypertension; 15.8% had an isolated systolic
hypertension, 2.7% an isolated diastolic hypertension, 13.1%
a hypertension stage 1, and 4.7% a hypertension stage 2.
Subjects with MDD were less often in the isolated systolic
group (remitted: 14.3%; current: 13.6% versus 18.3% in
controls) and less likely to have an isolated systolic hyper-
tension (remitted: odds ratio [OR]: 0.72, 95% CI: 0.53 to
0.98, P0.03; current: OR: 0.60; 95% CI: 0.44 to 0.82;
P0.001). Anxious subjects were not significantly more
likely to have any kind of hypertension. In addition, subjects
using a TCA had more often isolated diastolic hypertension
(6.0%), hypertension stage 1 (20.9%), or hypertension stage 2
(13.4%) compared with nonmedicated subjects (3.1%, 12.2%,
and 5.1%, respectively). TCA users were more likely to have
hypertension stage 1 (OR: 1.90; 95% CI: 0.94 to 3.84;
P0.07) and hypertension stage 2 (OR: 3.19; 95% CI: 1.35 to
7.55; P0.008). Finally, Table 3 shows that subjects using an
NS working antidepressant were more likely to have hyper-
tension stage 1 (OR: 1.72; 95% CI: 1.04 to 2.84; P0.03).
Leaving out subjects using antihypertensives from the anal-
yses (remaining: N2355) yielded very similar results.
Discussion
This large-scale cohort study showed that, when compared
with healthy controls, subjects with MDD have a significantly
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Table 2. Results of Regression Analyses Associating Depression, Anxiety, and Antidepressant Use With SBP and DBP
Variable
Unadjusted
Adjusted for Lifestyle and
Health Factors Additionally Adjusted for RSA Additionally Adjusted for HR
B P R 2 B P R 2 B P R 2 B P R 2
SBP, mm Hg
Model 0.011 0.304 0.306 0.316
Current MDD 3.052 0.002 2.452 0.003 2.491 0.003 2.350 0.004
Remitted MDD 1.842 0.06 1.827 0.03 1.913 0.02 1.740 0.04
Current anxiety disorder 0.833 0.34 0.475 0.52 0.449 0.55 0.466 0.53
Remitted anxiety disorder 0.661 0.56 0.765 0.43 0.743 0.44 0.730 0.45
Use of a TCA, yes vs no 10.093 0.001 5.388 0.008 4.845 0.02 3.173 0.12
Use of an SSRI, yes vs no 1.136 0.29 0.142 0.87 0.459 0.61 0.023 0.98
Use of NS working
antidepressant, yes vs no
3.607 0.03 1.287 0.36 0.866 0.54 0.570 0.69
Age, per 1-y increase 0.512 0.001 0.475 0.001 0.535 0.001
Sex, female vs male 9.567 0.001 9.356 0.001 10.256 0.001
Education, per 1-y increase 0.310 0.002 0.314 0.002 0.285 0.005
PA, per 1000 MET-min/wk
increase
0.010 0.92 0.014 0.89 0.046 0.66
BMI, per 1 kg/m2 increase 0.754 0.001 0.736 0.001 0.685 0.001
Alcohol, per 1 consumption
increase a day
1.470 0.001 1.482 0.001 1.464 0.001
Smoking, yes vs no 1.654 0.02 1.645 0.02 1.789 0.008
Chronic disease, per 1
disease increase
0.216 0.44 0.196 0.48 0.218 0.43
RSA, per 1 ms increase 0.032 0.009 0.005 0.73
HR, per 1 bpm increase 0.234 0.001
DBP
Model 0.020 0.265 0.277 0.307
Current MDD 0.541 0.33 0.384 0.43 0.441 0.36 0.306 0.52
Remitted MDD 0.258 0.65 0.050 0.92 0.178 0.72 0.011 0.98
Current anxiety disorder 0.368 0.47 0.953 0.03 0.915 0.04 0.932 0.03
Remitted anxiety disorder 0.436 0.51 0.148 0.80 0.180 0.75 0.193 0.73
Use of a TCA, yes vs no 8.453 0.001 5.468 0.001 4.666 0.001 3.058 0.009
Use of an SSRI, yes vs no 0.779 0.20 0.095 0.53 0.564 0.29 0.144 0.78
Use of NS working
antidepressant, yes vs no
3.347 0.001 2.052 0.01 1.430 0.09 1.144 0.16
Age, per 1-y increase 0.288 0.001 0.234 0.001 0.291 0.001
Sex, female vs male 1.961 0.001 1.650 0.001 2.516 0.001
Education, per 1-y increase 0.113 0.06 0.118 0.05 0.091 0.12
PA, per 1000 MET-min/wk
increase
0.124 0.04 0.118 0.05 0.088 0.14
BMI, per 1 kg/m2 increase 0.551 0.001 0.524 0.001 0.476 0.001
Alcohol, per 1 consumption
increase a day
0.722 0.001 0.739 0.001 0.722 0.001
Smoking, yes vs no 0.324 0.42 0.311 0.44 0.450 0.25
Chronic disease, per 1
disease increase
0.172 0.30 0.142 0.39 0.163 0.31
RSA, per 1 ms increase 0.047 0.001 0.012 0.12
HR, per 1 bpm increase 0.225 0.001
PA indicates physical activity; BMI, body mass index.
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lower mean SBP and are less likely to have isolated systolic
hypertension. Currently anxious subjects had a significantly
higher mean DBP (but not SBP) compared with controls,
although in our study it did not result in a significantly higher
risk of (isolated diastolic) hypertension. Patients using a TCA
had significantly higher SBP and DBP compared with con-
trols and nonmedicated patients and a clearly higher risk of
being clinically hypertensive (stage 1 or 2). The increase in
SBP was largely accounted for by the anticholinergic effects
of TCAs on vagal control over the heart. However, for DBP,
the effect of TCAs remained significant even after correcting
for RSA and HR, suggesting additional vascular effects of
TCAs. In addition, the use of NS working antidepressants
also increased DBP, and these subjects were more often
diagnosed as stage 1 hypertensive. These effects, however,
were fully accounted for by RSA and HR.
A review of Rutledge and Hogan8 reported an overall in-
creased hypertension risk among anxious subjects, which is in
line with our observed elevated DBP risk in anxious individ-
uals, although the hypertension risk did not reach signifi-
cance. However, they found an increased risk for hyperten-
sion for the depressed subjects as well, where we found a
decreased risk. Our results also differ from Yan et al11 and
Shinn et al,12 who found no association between anxiety and
depression with BP and hypertension risk. Our results are in
line, however, with those of Paterniti et al,10 who found high BP
in anxious subjects but low BP in depressed subjects. Low BP in
depressed subjects was also found by Hildrum et al.13,14
Several possible mechanisms for low BP in depression
have been hypothesized. First, depressed subjects may more
often use antihypertensive drugs and suffer from heart failure,
which may both reflect in lower BP levels. However, our
study did not find more antihypertensive users in the psycho-
pathology group than in the control group, and leaving out
antihypertensive users from the analyses did not change our
findings. In addition, subjects with known CVD, including
heart failure, were excluded from the analyses. Therefore, it is
not likely that heart failure or antihypertensive use is the
explanation for the low SBP found in depressive subjects in
this study.
A second explanation for the observed association is that
chronic low BP itself causes depression, eg, through somatic
symptoms and fatigue. This possibility was addressed in
recent longitudinal studies, although with inconsistent results:
Table 3. Association of Different Stages of Hypertension With MDD and Anxiety With and Without Antidepressants Estimated With a
Multinomial Logistic Regression Model
Psychopathology
Variable
Isolated Systolic Hypertension* Isolated Diastolic Hypertension† Hypertension Stage 1‡ Hypertension Stage 2§
% OR (95% CI) P % OR (95% CI) P % OR (95% CI) P % OR (95% CI) P
Current MDD
17.1 2.7 12.6 5.1No
Yes 13.6 0.60 (0.44 to 0.82) 0.001 2.7 0.83 (0.44 to 1.55) 0.56 13.9 0.96 (0.68 to 1.35) 0.81 3.9 0.92 (0.53 to 1.60) 0.77
Remitted MDD
16.4 2.7 13.3 4.1No
Yes 14.3 0.72 (0.53 to 0.98) 0.03 2.7 0.84 (0.44 to 1.58) 0.58 12.6 0.86 (0.61 to 1.22) 0.41 6.2 1.41 (0.85 to 2.33) 0.19
Current anxiety
disorder
15.9 2.5 13.5 4.8No
Yes 15.7 1.18 (0.90 to 1.55) 0.24 3.1 1.56 (0.87 to 2.79) 0.14 12.5 0.91 (0.67 to 1.23) 0.54 4.5 1.22 (0.76 to 1.97) 0.41
Remitted anxiety
disorder
16.1 2.6 13.2 4.7No
Yes 14.0 0.88 (0.61 to 1.26) 0.47 3.3 1.43 (0.70 to 2.91) 0.33 12.7 0.81 (0.55 to 1.19) 0.29 4.3 0.70 (0.38 to 1.30) 0.26
Use of a TCA
15.8 2.6 12.9 4.4No
Yes 16.4 1.43 (0.68 to 3.00) 0.34 6.0 2.12 (0.69 to 6.49) 0.19 20.9 1.90 (0.94 to 3.84) 0.07 13.4 3.19 (1.35 to 7.55) 0.008
Use of an SSRI
16.2 2.9 12.6 5.0No
Yes 14.2 0.94 (0.67 to 1.32) 0.71 2.0 0.57 (0.27 to 1.22) 0.15 15.7 1.23 (0.87 to 1.74) 0.25 3.1 0.59 (0.31 to 1.12) 0.10
Use of NS
working AD
15.8 2.8 12.7 4.6No
Yes 16.9 1.24 (0.75 to 2.07) 0.40 2.0 0.68 (0.20 to 2.28) 0.53 19.6 1.72 (1.04 to 2.84) 0.03 5.4 1.41 (0.61 to 3.23) 0.42
AD indicates antidepressant. Data were adjusted for age, sex, education, body mass index, physical activity, smoking, alcohol use, and chronic diseases.
*Isolated systolic hypertension: SBP 140 mm Hg and DBP 90 mm Hg.
†Isolated DBP: SBP 140 mm Hg and DBP 90 mm Hg.
‡Hypertension stage 1: SBP 140 mm Hg and DBP 90 mm Hg.
§Hypertension stage 2: SBP 160 mm Hg and DBP 100 mm Hg.
636 Hypertension April 2009
 at Vrije Universiteit--Amsterdam on May 12, 2009 hyper.ahajournals.orgDownloaded from 
some report that low BP at baseline is predictive for depres-
sive symptoms at follow-up but not the other way around,35
whereas others found the opposite to be true.14
A final explanation for the observed association does not
assume causality but instead assumes a common underlying
factor that independently increases the risk for depression, as
well as the likelihood to maintain a low BP level. The central
monoamine system may be a possible source of this common
factor.36,37 Depression and anxiety are characterized by al-
tered levels of neuropeptide Y, an important modulator of
norepinephrine signaling. The same alterations in neuropep-
tide Y may suppress sympathetic activity and decrease
BP.38,39 More research is needed to unravel the underlying
mechanisms involved in the low BP in depressed subjects.
The higher DBP in anxious individuals could reflect a
chronic state of psychological arousal in these subjects, which
is typically accompanied by increased sympathetic nervous
activity and decreased parasympathetic activity. At the car-
diac level, the shift in sympathovagal balance leads to an
increase in cardiac output; at the vascular level, the increased
norepinephrinergic drive may further increase the peripheral
resistance. Both effects can, in principle, explain the increase
in DBP. Correcting for HR, a major indicator of cardiac
output, did not remove the association between current
anxiety disorder and DBP. Our analyses suggest, therefore,
that anxiety mainly acts through vascular effects. The asso-
ciation between the use of TCA or NS working antidepres-
sants and high BP was found earlier by several small
studies.40–43
Because our results are based on cross-sectional data, we
cannot make any assumptions on causality in these relations.
Whether low BP predicts depression, whether anxiety pre-
dicts high BP or the other way around, and whether the start
of antidepressant use causes high BP or finishing antidepres-
sant use ceases the risk on hypertension remain to be studied
with longitudinal analyses. In addition, we were unable to
investigate whether the found associations between certain
antidepressants and BP and hypertension were mediated by
sympathetic control over the heart, because a measure for
pure sympathetic activity was missing. These study limita-
tions were balanced by strong points: our study sample was
large and included both medicated and nonmedicated subjects
with psychopathology, as well as healthy controls. We were able
to study continuous BP, as well as a more clinic categorical
hypertension measure, and could examine the additional contri-
bution of CVC measures.
Perspectives
Our results provide no support for the hypothesis that the
association between depression and cardiac diseases partly
derives from an effect of depression on BP. Depression is
associated with lower, not higher, BP. However, our results
do partly support this hypothesis for the association with
anxiety disorders. These findings have consequences for BP
research, because it seems clearly meaningful to take the
specific psychopathological status of participants into ac-
count when testing determinants of interindividual variation
in BP. Our findings also have consequences for the pharma-
cological treatment of depressive and anxiety disorders.
TCAs (and, to a lower degree, NS working antidepressants)
have a detrimental effect on BP, partly through their effect on
vagal control over the heart. When treating depressive or
anxiety disorders, especially in patients with comorbid CVD,
SSRIs may be the most likely choice. If these fail to show
clinical efficacy, TCA and NS working antidepressant use
should be paired to careful BP monitoring in these patients.
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